Vimarsana
Biggest News Aggregation in the World

Page 9 - Controlled Trials News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Controlled Trials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Controlled Trials Today - Breaking & Trending Today

Sham Acupuncture Needling at Acupuncture Points Is Not a True Placebo Control - Vimarsana News

Sham Acupuncture Needling at Acupuncture Points Is Not a True Placebo Control

Researchers found that sham acupuncture needling at previously used acupuncture points was not a true placebo.

GSK : and ViiV Healthcare to present scientific advancements in their industry-leading infectious diseases portfolio at IDWeek 2023 -October 10, 2023 at 07:17 am EDT - Vimarsana News

GSK : and ViiV Healthcare to present scientific advancements in their industry-leading infectious diseases portfolio at IDWeek 2023 -October 10, 2023 at 07:17 am EDT

First scientific presentation of RSV vaccine efficacy and safety data over two seasons New public health impact modelling study data on meningococcal B...

Psychotherapy Improves Mental Health But Not IBD Disease Activity - Vimarsana News

Psychotherapy Improves Mental Health But Not IBD Disease Activity

Psychological therapies have no effect on IBD disease activity despite beneficial effects on anxiety, depression, and QOL.

Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis | Otolaryngology | JAMA - Vimarsana News

Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis | Otolaryngology | JAMA

This systematic review and dose-response meta-analysis evaluates the efficacy and tolerability of gefapixant, a new P2X3 antagonist, for the treatment of adults

Dealing with Australia's digital trade dilemma - Vimarsana News

Dealing with Australia's digital trade dilemma

Australia, a one-time pioneer in international trade systems, has fallen behind, complicating ambitions for a post-pandemic recovery